Crossmark

Aromatase inhibitor-induced bone loss osteosarcopenia in older patients with breast cancer: effects of the RANK/RANKL system’s inhibitor denosumab vs. bisphosphonates

Crossref DOI link: https://doi.org/10.1007/s11739-024-03725-1

Published Online: 2024-08-02

Published Print: 2024-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Casabella, Andrea https://orcid.org/0000-0002-1406-0114
Paladin, Francesca https://orcid.org/0000-0003-3526-5503
Bighin, Claudia https://orcid.org/0000-0001-9956-0216
Ottaviani, Silvia https://orcid.org/0000-0002-8278-793X
Marelli, Cristina https://orcid.org/0000-0003-1510-1819
Ponzano, Marta https://orcid.org/0000-0003-4091-4686
Signori, Alessio https://orcid.org/0000-0001-6289-9144
Murdaca, Giuseppe https://orcid.org/0000-0002-6403-6905
Cutolo, Maurizio https://orcid.org/0000-0002-5396-0932
Molfetta, Luigi https://orcid.org/0000-0001-8789-4964
Nencioni, Alessio https://orcid.org/0000-0001-5068-8884
Paolino, Sabrina https://orcid.org/0000-0001-9269-5089
Del Mastro, Lucia https://orcid.org/0000-0002-9546-5841
Monacelli, Fiammetta https://orcid.org/0000-0003-4303-7252
License Information

Text and Data Mining valid from 2024-08-02

Version of Record valid from 2024-08-02
More Information

Article History

Received: 26 January 2024

Accepted: 3 July 2024

First Online: 2 August 2024

Declarations

:

: All authors have no competing interests with any organization or entity with a financial interest in competition with the subject, matter or materials discussed in the manuscript.

: This study was conducted in accordance with the Ethics Committee.

: Informed consent was waived because of the retrospective nature of the study and the analysis used anonymous clinical data.

Document is current

Any future updates will be listed below